Table 2.

Phase II Clinical Trials of KIs in Patients with MTC

Drug	Study	No. of Patients	PR, %	PFS, mo	Ref.
Cabozantinib	Phase II	37	29	NA	50
Imatinib	Phase II	9	0	NA	53
Imatinib	Phase II	15	0	NA	52
Motesanib	Phase II	91	2	12	45
Sorafenib	Phase II	16	6	17.9	46
Sorafenib plus tipifarnib	Phase II	13	38	15	55
Sunitinib	Phase II	6	50	NA	44
Vandetanib (300 mg/d)	Phase II	30	20	27.9	48
Vandetanib (100 mg/d)	Phase II	19	16	NA	49

Abbreviations: PR, partial response (RECIST); NA, not available.